Today: 9 November 2025
Subscribe
Browse Category

Pharma Industry News 29 September 2025 - 20 October 2025

Rani Therapeutics (RANI) Stock Skyrockets ~200% on $1B Pharma Deal – Will the Rally Last?

Rani Therapeutics (RANI) Stock Skyrockets ~200% on $1B Pharma Deal – Will the Rally Last?

RANI Stock Price Skyrockets on Deal News Rani’s stock price skyrocketed after the company unveiled its landmark partnership and financing news. On Friday, Oct. 17, 2025, RANI opened around $1.37 and surged as high as $2.39 intraday before settling at a $1.64 closing price – a stunning +248% one-day gain investing.com. The prior day, RANI had closed at just $0.47, so the news sparked an almost threefold leap in value. In pre-market trading before the open, the stock had already jumped over +150%, and it continued to rally after the bell ts2.tech ts2.tech. By midday Oct. 17, shares were still
20 October 2025
 ·  ·  ·  ·  · 
Disc Medicine (IRON) Stock Soars on FDA Fast-Track News as Analysts Boost Targets

Disc Medicine (IRON) Stock Soars on FDA Fast-Track News as Analysts Boost Targets

FDA Voucher Ignites IRON Stock Rally Disc Medicine’s stock price (NASDAQ: IRON) spiked dramatically in mid-October 2025 after news of the FDA voucher, vaulting from the mid-$70s to the low-$90s in a single day gurufocus.com. On Friday (Oct. 17), IRON opened around $85 and surged to an intraday high of $92.50 before closing at $93.00, marking a ~25% jump on the day stockanalysis.com. This leap capped a steady uptrend over the past month – the shares were trading near $60 in early September and gradually climbed into the $70s as anticipation built around bitopertin’s NDA filing and review stockanalysis.com stockanalysis.com.
17 October 2025
 ·  ·  ·  · 
Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next?

Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next?

Novo Nordisk Licensing Deal Sparks Rally On Oct. 15, Novo Nordisk (NYSE: NVO) and Omeros announced a landmark deal licensing zaltenibart (OMS906), Omeros’s experimental MASP-3 inhibitor for rare blood/kidney diseases investor.omeros.com. Under the agreement, Novo pays $340M upfront and can pay up to $2.1 billion in total milestones and royalties for exclusive global rights investor.omeros.com reuters.com. Reuters reports that Omeros stock “more than doubled to $9.90” in early trading after the news reuters.com, and by market close had settled near $10.10 investing.com. TechStock² (ts2.tech) notes Omeros shares surged roughly 65% on the announcement ts2.tech. The deal is structured as an
15 October 2025
 ·  ·  ·  ·  ·  · 
Recursion RXRX Stock Skyrockets: AI Breakthroughs and Big Pharma Deals Ignite Biotech Surge

Recursion RXRX Stock Skyrockets: AI Breakthroughs and Big Pharma Deals Ignite Biotech Surge

Volatile Stock Performance in October 2025 Recursion’s stock showed wild swings in early October. On Oct 7, 2025 the shares fell about 5.4% to ~$5.23 amid a broad market slump nasdaq.com. The very next day (Oct 8) the stock rebounded sharply, jumping roughly 16% to ~$6.08 ts2.tech. This put RXRX near the middle of its 52-week trading range (about $3.97–$10.87) ts2.tech. Trading volume on these moves was heavy, with tens of millions of shares changing hands as investors positioned for upcoming company news. By Oct 14, RXRX was around $5.89 stocktitan.net. This volatility appears driven by renewed enthusiasm for Recursion’s
15 October 2025
 ·  ·  ·  ·  · 
Astria Therapeutics Stock Skyrockets 53% After $700M Buyout – What’s Next?

Astria Therapeutics Stock Skyrockets 53% After $700M Buyout – What’s Next?

Latest News & Developments On Oct. 14, 2025, Astria was swept into the headlines by a surprise $700+ million takeover. BioCryst Pharmaceuticals announced a definitive merger agreement to acquire Astria for $8.55 in cash plus 0.59 shares of BioCryst stock per Astria share (≈$13.00 total) marketscreener.com reuters.com. This values Astria at roughly $920M equity and $700M enterprise stocktitan.net. The Boards of both companies approved the deal, which is expected to close in Q1 2026 (subject to approvals) stocktitan.net. Astria CEO Jill Milne will join BioCryst’s board post-merger stocktitan.net. Market reaction: News of the deal caused Astria’s stock to jump sharply.
14 October 2025
 ·  ·  ·  ·  ·  · 
NewAmsterdam Pharma (NAMS) Stock Soars on Cholesterol Drug Breakthrough – What Investors Should Know

NewAmsterdam Pharma (NAMS) Stock Soars on Cholesterol Drug Breakthrough – What Investors Should Know

Company Overview: History & Mission NewAmsterdam Pharma Company N.V. is a Netherlands-based biotech (with U.S. operations in Miami) on a mission to “change the landscape of lipid-lowering treatment” for cardiovascular disease newamsterdampharma.com. Founded in early 2020, the company sprang from the vision of Prof. John J.P. Kastelein – a world-renowned expert in lipid disorders – and venture capital firm Forbion newamsterdampharma.com. They acquired the rights to obicetrapib, a once-abandoned CETP inhibitor, from an Amgen subsidiary in 2020 newamsterdampharma.com. Soon after, Dr. Michael Davidson (a leading preventive cardiologist) joined as co-founder and CEO, bringing deep clinical expertise to the leadership team
11 October 2025
 ·  ·  ·  ·  · 
Akero Therapeutics (AKRO) Skyrockets on $5.2 B Novo Nordisk Buyout – Pipeline Breakthroughs & Expert Outlook

Akero Therapeutics (AKRO) Skyrockets on $5.2 B Novo Nordisk Buyout – Pipeline Breakthroughs & Expert Outlook

Sources: Akero Therapeutics investor materials; Novo Nordisk press statements; Reuters, TS2.tech and FierceBiotechnews reports ts2.tech ts2.tech fiercebiotech.com; MarketBeat and DirectorsTalk analyst surveys marketbeat.com directorstalkinterviews.com; Economic Times deal summary economictimes.indiatimes.com economictimes.indiatimes.com; Business Wire legal alert businesswire.com businesswire.com; and TradingView market data marketbeat.com tradingview.com.
9 October 2025
 ·  ·  ·  ·  ·  · 
AI Drug Discovery Goldmine? Inside Recursion Pharma’s Wild Stock Surge and What’s Next

AI Drug Discovery Goldmine? Inside Recursion Pharma’s Wild Stock Surge and What’s Next

Latest News (Oct 7–Oct 9, 2025) Stock Performance & Technical Analysis After languishing through the summer, Recursion’s share price came to life in early October 2025. By Oct 8 the stock had rebounded to around $6.09 insidermonkey.com, putting it near the middle of its volatile 52-week range ($3.97 – $10.87) ts2.tech. For context, RXRX had traded in the double-digits when AI hype in biotech peaked earlier in the year, then slid into the high-$3s during industry sell-offs ts2.tech. Even after this week’s pop, shares remain ~30% lower than a year ago (amid a broader biotech downturn) ts2.tech. Such dramatic swings
9 October 2025
 ·  ·  ·  ·  · 
Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Pfizer Stock Soars After Trump’s Drug Deal and Obesity Bet – Is This the Start of a Comeback?

Stock Performance: From Laggard to Late-September Lift For much of 2025, Pfizer’s stock was stuck in a rut – but that changed dramatically as Q4 approached. By late September, PFE had drifted down near multi-year lows around $23, reflecting a post-pandemic hangover. As of Sept 25, the stock was down roughly 9% year-to-date and about 18% below its level one year prior ts2.tech. It traded near the bottom of its 52-week range ($20.92 – $30.43), weighed down by steep declines in COVID vaccine and pill sales and general pessimism on its growth prospects ts2.tech ts2.tech. In fact, Pfizer’s COVID-driven revenues
6 October 2025
 ·  ·  ·  ·  ·  ·  · 
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly Stock Rockets on GLP‑1 Boom and New Approvals: Is LLY the Next Trillion‑Dollar Pharma Titan?

In‑Depth Report Introduction Eli Lilly and Company (NYSE: LLY) has become the poster‑child for the emerging class of GLP‑1‑based obesity and diabetes therapies. Its injectable tirzepatide products Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management) have delivered explosive growth, propelling the company’s market capitalization into the high‑hundred‑billion range. On 6 Oct 2025, LLY traded around $840, close to its all‑time highs marketbeat.com. The company’s pivot toward metabolic and neurodegenerative diseases, combined with an aggressive manufacturing expansion, has made it one of the most closely watched stocks on Wall Street. Stock Performance and Valuation After an extraordinary rally in late September 2025, LLY opened
6 October 2025
 ·  ·  ·  ·  · 
Biotech Bombshell: MoonLake (MLTX) Shares Tumble 85% on Trial News – Is a $108 Price Target Still Real?

Biotech Bombshell: MoonLake (MLTX) Shares Tumble 85% on Trial News – Is a $108 Price Target Still Real?

Sources: Company filings and press releases globenewswire.com stocktitan.net; financial media (Reuters, Investing.com, Stocktwits, Seeking Alpha) reuters.com stocktwits.com investing.com; market data services stocktitan.net tipranks.com. All figures and quotes are from cited reports.
29 September 2025
 ·  ·  ·  ·  ·  · 
1 2
Go toTop